Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 3/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634281 | 0.89 | CYP3A4 (0.41) | CYP3A4CYP2C9ALDH1A1MAPT | |
| SCHEMBL5045178 | 0.85 | CYP2C9 (0.52) | CYP3A4CYP2C9ALDH1A1HPGDTSHR | |
| SCHEMBL5040717 | 0.85 | CYP2C9 (0.52) | CYP3A4CYP2C9ALDH1A1HPGDTSHR | |
| SCHEMBL1818094 | 0.77 | CYP3A4 (0.36) | CYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL5840196 | 0.77 | CYP3A4 (0.41) | CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL1814419 | 0.70 | CYP3A4 (0.35) | CYP3A4CYP2C9 | |
| SCHEMBL6061289 | 0.69 | CYP3A4 (0.33) | CYP3A4CYP2C9KMT2A | |
| SCHEMBL5747928 | 0.68 | CYP3A4 (0.43) | CYP3A4CYP2C9 | |
| SCHEMBL1218640 | 0.68 | CYP3A4 (0.43) | CYP3A4CYP2C9 | |
| SCHEMBL1217601 | 0.68 | CYP3A4 (0.43) | CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0971922-B1 | TETRAHYDROPYRIDO COMPOUNDS | ALTANA PHARMA AG (DE) | 2004-04-28 | — | — | EP | claimed |
| US-6197783-B1 | THERAPY FOR GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-06 | — | — | US | claimed |
| EP-0971922-A1 | TETRAHYDROPYRIDO COMPOUNDS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2000-01-19 | — | — | EP | claimed |
| WO-1998042707-A1 | TETRAHYDROPYRIDO COMPOUNDS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-10-01 | — | — | WO | claimed |
| US-7196196-B2 | Substituted imidazo[1, 2-a]-5,6,7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo[1,2-a]pyridines | BASF AKTIENGESELLSCHAFT (DE) | 2007-03-27 | — | — | US | disclosed |
| US-20050020620-A1 | Substituted imidazo[1, 2-a]-5,6,7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo[1,2-a]pyridines | BASF AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
| EP-0971922-B1 | TETRAHYDROPYRIDO COMPOUNDS | ALTANA PHARMA AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-6197783-B1 | THERAPY FOR GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-03-06 | — | — | US | disclosed |
| EP-0971922-A1 | TETRAHYDROPYRIDO COMPOUNDS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042707-A1 | TETRAHYDROPYRIDO COMPOUNDS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020620-A1 | Substituted imidazo[1, 2-a]-5,6,7,8-tetrahydropyridine-8-ones, method for their production and the use thereof for producing imidazo[1,2-a]pyridines | BTN3A1, DHPS, NISCH | CYP3A4 48/4885CYP2C9 249/4885SMN1; SMN2 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.